Michael D. Lockshin, MD

Co-Investigators

Doruk Erkan, MD

Summary

The purpose of this study is to assess the efficacy of rituximab compared with placebo for the treatment of patients with active systemic lupus erythematosus (SLE).  This is a multi-center trial in which patients will be followed for 18 months.

Inclusion/Exclusion Criteria

Patient must have active SLE despite treatment at the time of enrollment.

Contact Information

JoAnn Vega
212.774.2795
vegaj@hss.edu